首頁>美國衛(wèi)生研究院文獻>Blood and Lymphatic Cancer: Targets and Therapy

Blood and Lymphatic Cancer: Targets and Therapy

【機譯】：血液和淋巴癌癥的目標和治療

ISSN：-
出版周期：Irregular
語言：English

起始發(fā)布年份：2011
出版者：[Auckland, N.Z.] : Dove Medical Press, [2011]-
出版地：New Zealand

數(shù)據(jù)庫引入：PubMed: v6, 2016-, PMC

MeSH詞表主題詞：Hematology*; Leukemia, Lymphoid*; Lymphatic Metastasis*

備注：Articles added irregularly during the year and collected into annual issues.展開▼

期刊論文

熱門論文

年度選擇

2024
- Volume 14(14)??2024
2023
- Volume 13(13)??2023
2022
- Volume 12(12)??2022
2021
- Volume 11??2021
- Volume 11(11)??2021
2020
- Volume 10??2020
2019
- Volume 9??2019
2018
- Volume 8??2018
2017
- Volume 7??2017
2016
- Volume 6??2016

更多>>

全選（0）

1.IDH1-mutated relapsed or refractory AML: current challenges and future prospects

機譯：IDH1突變的復(fù)發(fā)性或難治性AML：當前的挑戰(zhàn)和未來的前景
- 作者：Juan Eduardo Megías-Vericat;Octavio Ballesta-López;Eva Barragán;Pau Montesinos
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2019年第-1期
- isocitrate dehydrogenase 1 acute myeloid leukemia relapsed/refractory ivosidenib FT-2102 venetoclax;
2.Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma

機譯：在霍奇金淋巴瘤的治療中通過程序性死亡1阻斷來利用免疫系統(tǒng)
- 作者：Melody B Oncale;Hossein Maymani;Loretta J Nastoupil
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2017年第-1期
- Hodgkin lymphoma programmed death-1 nivolumab pembrolizumab lymphoma;
3.Clinical potential of midostaurin in advanced systemic mastocytosis

機譯：Midostaurin在晚期全身肥大細胞增多癥中的臨床潛力
- 作者：Marie Olivia Chandesris;Gandhi Damaj;Olivier Lortholary;Olivier Hermine
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2017年第-1期
- aggressive systemic mastocytosis mast cell leukemia tyrosine kinase inhibitor midostaurin;
4.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies

機譯：復(fù)發(fā)/難治性霍奇金淋巴瘤的病理生理學(xué)和治療進展重點是靶向治療和移植策略
- 作者：Theodoros Karantanos;Ioannis Politikos;Vassiliki A Boussiotis
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2017年第-1期
- relapsed/refractory Hodgkin’s lymphoma pathophysiology novel agents immunotherapy hematopoietic stem cell transplantation;
5.Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

機譯：卡非佐米在二線治療及以后用于復(fù)發(fā)性多發(fā)性骨髓瘤的應(yīng)用
- 作者：Divaya Bhutani;Jeffrey A Zonder
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2017年第-1期
- multiple myeloma carfilzomib relapsed/refractory;
6.Complications and management of coagulation disorders in leukemia patients

機譯：白血病患者凝血功能障礙的并發(fā)癥和處理
- 作者：Deepesh Lad;Arihant Jain;Subhash Varma
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2017年第-1期
- leukemia coagulation thrombosis bleeding;
7.Impact of obinutuzumab alone and in combination for follicular lymphoma

機譯：奧比妥單抗單獨和聯(lián)合使用對卵泡性淋巴瘤的影響
- 作者：Maryam Sarraf Yazdy;Bruce D Cheson
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2017年第-1期
- obinutuzumab follicular lymphoma MRD monoclonal antibody;
8.Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects

機譯：彈性漿細胞樣樹突狀細胞瘤：挑戰(zhàn)和未來前景
- 作者：Amy M Trottier;Sonia Cerquozzi;Carolyn J Owen
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2017年第-1期
- BPDCN myeloid neoplasm cutaneous dendritic cell;
9.Uptake of lymphoma-derived exosomes by peripheral blood leukocytes

機譯：外周血白細胞攝取淋巴瘤來源的外來體
- 作者：Heather R Ferguson Bennit;Amber Gonda;Laura J Oppegard;David P Chi;Salma Khan;Nathan R Wall
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2017年第-1期
- exosome non-Hodgkin’s lymphoma B cell;
10.Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

機譯：伊達拉西布治療惰性B細胞惡性腫瘤：慢性淋巴細胞白血病和小淋巴細胞或濾泡性淋巴瘤
- 作者：Yazan F Madanat;Mitchell R Smith;Alexandru Almasan;Brian T Hill
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2016年第-1期
- idelalisib PI3Kδ inhibitors chronic lymphocytic leukemia follicular lymphoma;
11.Ruxolitinib: a targeted treatment option for patients with polycythemia vera

機譯：魯索替尼：真性紅細胞增多癥患者的靶向治療選擇
- 作者：Kris Vaddi;Srdan Verstovsek;Jean-Jacques Kiladjian
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2016年第-1期
- myeloproliferative disorder polycythemia vera Janus kinase inhibitor;
12.Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes

機譯：評估和監(jiān)測接受化療的多發(fā)性骨髓瘤患者：改善預(yù)后的策略
- 作者：Beth Faiman;Jason Valent
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2016年第-1期
- multiple myeloma treatment symptoms assessment monitoring symptom management targeted therapies;
13.Managing treatment-related peripheral neuropathy in patients with multiple myeloma

機譯：多發(fā)性骨髓瘤患者治療相關(guān)的周圍神經(jīng)病變的處理
- 作者：Sara Grammatico;Laura Cesini;Maria Teresa Petrucci
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2016年第-1期
- neurotoxicity thalidomide-induced peripheral neuropathy bortezomib-induced peripheral neuropathy;
14.Waldenstr?m macroglobulinemia: biology genetics and therapy

機譯：Waldenstr?m巨球蛋白血癥：生物學(xué)遺傳學(xué)和治療
- 作者：Jonas Paludo;Stephen M Ansell
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2016年第-1期
- Bruton’s tyrosine kinase ibrutinib lymphoplasmacytic lymphoma Waldenstr?m macroglobulinemia;
15.Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives

機譯：ponatinib在慢性粒細胞白血病和費城染色體陽性急性淋巴細胞白血病中的應(yīng)用：患者選擇和觀點
- 作者：Theodora Anagnostou;Mark R Litzow
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2018年第-1期
- ponatinib acute lymphoblastic leukemia chronic myeloid leukemia patient selection;
16.Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions

機譯：悶燒多發(fā)性骨髓瘤：流行和當前證據(jù)指導(dǎo)治療決策
- 作者：Agnieszka Blum;Despina Bazou;Peter O’Gorman
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2018年第-1期
- smoldering multiple myeloma risk factor biomarker genomic aberrations glycan analysis;
17.Current understanding of the role and regulation of miRNAs in Burkitt lymphoma

機譯：目前對Burkitt淋巴瘤中miRNA的作用和調(diào)控的了解
- 作者：Alessandro Davide Videtta;Valeria Malagnino;Giulia De Falco
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2018年第-1期
- Burkitt lymphoma miRNAs MYC;
18.Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia

機譯：B細胞急性淋巴細胞白血病的生物學(xué)和治療方法的最新進展
- 作者：Mehrdad Hefazi;Mark R Litzow
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2018年第-1期
- acute lymphoblastic leukemia minimal residual disease hematopoietic cell transplantation Philadelphia chromosome monoclonal antibodies;
19.Plasmablastic lymphoma: current perspectives

機譯：漿母細胞性淋巴瘤：當前觀點
- 作者：Andres Lopez;Pau Abrisqueta
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2018年第-1期
- plasmablastic lymphoma review;
20.Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era

機譯：正電子發(fā)射斷層掃描時代晚期霍奇金淋巴瘤化療后的結(jié)局和復(fù)發(fā)方式
- 作者：Carminia Lapuz;Anoop K Enjeti;Peter C O’Brien;Anne L Capp;Elizabeth G Holliday;Sanjiv A Gupta
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2018年第-1期
- Hodgkin lymphoma advanced PET scan;
21.Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives Erratum

機譯：ponatinib在慢性粒細胞白血病和費城染色體陽性急性淋巴細胞白血病治療中的應(yīng)用：患者選擇和觀點勘誤
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2018年第-1期
22.Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens

機譯：EPOCH聯(lián)合利妥昔單抗/ R-CHOP方案治療雙發(fā)性彌漫性大B細胞淋巴瘤CD5表達的預(yù)后分析和療效比較
- 作者：Fangwen Zhang;Ling Li;Lei Zhang;Xin Li;Xiaorui Fu;Xinhua Wang;Jingjing Wu;Zhenchang Sun;Fei Kong;Liangliang Ren;Mingzhi Zhang
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2019年第-1期
- CD5 DA-EPOCH-R R-CHOP diffuse large B-cell lymphoma double-hit treatment prognosis;
23.Strategies for minimal residual disease detection: current perspectives

機譯：最小殘留疾病檢測的策略：當前觀點
- 作者：Giacomo Andreani;Daniela Cilloni
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2019年第-1期
- minimal residual disease;
- acute leukemia;
- multiparameter flow cytometry;
- real-time quantitative polymerase chain reaction;
- next-generation sequencing;
- digital PCR;
24.The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma

機譯：Venetoclax在慢性淋巴細胞白血病和小淋巴細胞淋巴瘤中的擴展作用
- 作者：Michael Schieber;Shuo Ma
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2019年第-1期
- CLL;
- SLL;
- venetoclax;
- BCL2;
25.Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells

機譯：針對慢性粒細胞白血病干細胞的策略
- 作者：Giovanna Carrà;Antonio Cartellà;Beatrice Maffeo;Alessandro Morotti
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2019年第-1期
- chronic myeloid leukaemia;
- stem cells;
- tyrosine kinase inhibitors;
26.The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

機譯：Brentuximab Vedotin在經(jīng)典霍奇金淋巴瘤中的演變作用
- 作者：Catherine Lai;Adrese Michael Kandahari;Chaitra Ujjani
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2019年第-1期
- antibody-drug conjugate;
- brentuximab vedotin;
- CD30;
- immunotherapy;
- classical Hodgkin lymphoma;
- novel therapies;
27.Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits Cell Proliferation In Leukemic Cell Lines HL60 And KG1

機譯：CRISPR / Cas9敲除BIRC5基因可誘導(dǎo)白血病細胞株HL60和KG1凋亡并抑制細胞增殖
- 作者：Manizheh Narimani;Mohammadreza Sharifi;Ali Jalili
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2019年第-1期
- survivin;
- CRISPR/Cas9 nuclease;
- AML;
- KG1 cells;
- HL60 cell;
28.The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

機譯：年齡對CLL患者存活的影響接受Ibrutinib作為初始治療
- 作者：Chaitra Ujjani;Anthony Mato;Brian T Hill;John N Allan;Frederick Lansigan;Ryan Jacobs;Alan Skarbnik;Hande Tuncer;John Pagel;Danielle Brander;Bruce Cheson;Paul Barr;Lindsey E Roeker;Jeffrey Pu;Nirav N Shah;Andre Goy;Stephen J Schuster;Nicole Lamanna;Alison Sehgal;Constantine S Tam;Mazyar Shadman
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2020年第-1期
- CLL;
- ibrutinib;
- elderly;
29.Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design Development and Place in Therapy

機譯：評估BLINATUMOMAB用于治療復(fù)發(fā)/難治性所有：設(shè)計開發(fā)和治療中的位置
- 作者：Audrey M Sigmund;Kieran D Sahasrabudhe;Bhavana Bhatnagar
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2020年第-1期
- blinatumomab;
- BiTE antibody;
- B-cell acute lymphoblastic leukemia;
- relapsed and refractory disease;
- measurable residual disease;
- MRD;
30.The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study

機譯：肥胖對急性淋巴細胞白血病成人患者的影響 - 單一中心回顧性研究
- 作者：Qiuju Liu;Brittny Major;Jennifer Le-Rademacher;Aref A Al-Kali;Hassan Alkhateeb;Kebede Begna;Michelle A Elliott;Naseema Gangat;William J Hogan;C Christopher Hook;Scott H Kaufmann;Animesh Pardanani;Mrinal S Patnaik;Ayalew Tefferi;Alexandra P Wolanskyj-Spinner;Wei Wei;Mark R Litzow
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2021年第-1期
- acute lymphoblastic leukemia;
- obesity;
- overweight;
- B cell;
- T cell;
31.BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma

機譯：BCL2家族抑制劑在多發(fā)性骨髓瘤的生物學(xué)和治療中
- 作者：Vikas A Gupta;James Ackley;Jonathan L Kaufman;Lawrence H Boise
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2021年第-1期
- multiple myeloma;
- BCL2 family inhibitors;
- venetoclax;
32.Clinical Utility of Pegaspargase in Children Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review

機譯：急性淋巴細胞白血病兒童青少年和年輕成年患者Pegaspargase的臨床效用：綜述
- 作者：Cynthia Bender;Luke Maese;Maria Carter-Febres;Anupam Verma
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2021年第-1期
- asparagine;
- asparaginase;
- serum asparaginase activity;
- toxicity;
33.Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence

機譯：Ivosidenib在急性髓性白血病患者管理中的療效和安全性曲線（AML）：新出現(xiàn)證據(jù)的更新
- 作者：Galia Stemer;Jacob M Rowe;Yishai Ofran
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2021年第-1期
34.Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma

機譯：復(fù)發(fā)/難治性濾泡淋巴瘤患者管理的最新進展
- 作者：Georgios Pongas;Bruce Cheson
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2021年第-1期
35.Differential Diagnosis of Waldenstr?m’s Macroglobulinemia and Early Management: Perspectives from Clinical Practice

機譯：Waldenstr?m 巨球蛋白血癥的鑒別診斷和早期管理：臨床實踐的觀點
- 作者：Surbhi Sidana;Shashank Cingam
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
36.AC024896.1/miR-363-3p Axis Regulates the Malignant Progression of Acute Myeloid Leukemia by Cuproptosis-Related Gene MYO1B

機譯：AC024896.1/miR-363-3p 軸通過銅矮病相關(guān)基因 MYO1B 調(diào)控急性髓系白血病的惡性進展
- 作者：Bo Liu;Yuhuan Zheng;Jie Zhang;Hongjuan Liu
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2024年第14期
37.Albumin-to-Globulin Ratio Combined with Neutrophil-to-Lymphocyte Ratio as a Prognostic Predictor in Multiple Myeloma with Renal Impairment

機譯：白蛋白與球蛋白比值聯(lián)合中性粒細胞與淋巴細胞比值作為多發(fā)性骨髓瘤伴腎功能不全的預(yù)后預(yù)測因子
- 作者：Yaoquan Zhang;Hong Hu;Yingzi Zhang;Xiajuan Yao;Ying Cai;Zhuyun Chen;Wenkai Xia;Zhongke Qin
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2024年第14期
38.Successful Anatomy Adapted Therapeutic Management and Genetic Profiling of Primary Pituitary Diffuse Large B-Cell Lymphoma

機譯：原發(fā)性垂體彌漫性大 B 細胞淋巴瘤的成功解剖適應(yīng)性治療管理和遺傳分析
- 作者：Vivek Gupta;Han W Tun;ErinMarie O Kimbrough;Liuyan Jiang
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2023年第13期
39.HIV/AIDS Associated Lymphoma: Review

機譯：HIV/AIDS 相關(guān)淋巴瘤：綜述
- 作者：Biruk Bayleyegn;Zegeye Getaneh;Ayenew Berhan
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
40.Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation

機譯：淋巴瘤相關(guān)腦葡萄糖代謝減退的神經(jīng)精神表現(xiàn)可以通過強化葡萄糖補充劑來逆轉(zhuǎn)
- 作者：Madiha Iqbal;Adam M Kase;Catherine Bullock;Ephraim E Parent;Muhamad Alhaj Moustafa;Ricardo Parrondo;Han Tun;K David Li
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
41.Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies

機譯：難治性伯基特淋巴瘤：診斷和干預(yù)策略
- 作者：Anna Maria Testi;Maria Luisa Moleti;Francesco Malfona;Sabina Chiaretti
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2024年第14期
42.Highly Curative Treatment of High-Risk Acute Promyelocytic Leukemia: Induction and Consolidation with ATRA+ATO+anthracyclines and Maintenance with ATRA+RIF

機譯：高危急性早幼粒細胞白血病的高治愈性治療：ATRA+ATO + 蒽環(huán)類藥物的誘導(dǎo)和鞏固以及 ATRA+RIF 的維持治療
- 作者：Erling Chen;Xuhan Zhang;Xing Hu;Lei Xue;Juan Tong;Dan Liu;Na Zhao;Changcheng Zheng;Li Wang
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2024年第14期
43.Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance

機譯：BTK 抑制劑在慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）中的應(yīng)用：實用指南
- 作者：Frédérique St-Pierre;Shuo Ma
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
44.CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges

機譯：多發(fā)性骨髓瘤患者的 CAR T 細胞療法：當前證據(jù)和挑戰(zhàn)
- 作者：Liem Minh Phan;Jacinth J Joseph;Matthew J Rendo;Christin B DeStefano
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
45.Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia

機譯：急性淋巴細胞白血病可測量殘留病灶的臨床價值
- 作者：Nicholas Short;Kyaw Hein;Musa Yilmaz;Elias Jabbour
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
46.Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission

機譯：成功進行長期緩解的雙重打擊 Richter 轉(zhuǎn)化的非移植治療
- 作者：Karan Seegobin;Han W Tun;Liuyan Jiang;Muhamad Alhaj Moustafa
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2021年第11期
47.Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma

機譯：人類免疫缺陷病毒相關(guān)非霍奇金淋巴瘤
- 作者：Zewudu Mulatie;Fikir Asrie;Tesfaye Gessese
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2023年第13期
48.FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation

機譯：FLT3 抑制劑作為同種異體干細胞移植后的維持治療
- 作者：Ibrahim Aldoss;Brian J Ball;Amanda Blackmon
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
49.Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article

機譯：多發(fā)性骨髓瘤的鑒別診斷及治療進展：綜述文章
- 作者：Munawwar Hussain;Sarvari Yellapragada;Samer Al Hadidi
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2023年第13期
50.Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma

機譯：依魯替尼治療新診斷的原發(fā)性中樞神經(jīng)系統(tǒng)淋巴瘤老年患者的長期生存率
- 作者：Vivek Gupta;Liuyan Jiang;Han W Tun;Muhamad Alhaj Moustafa;Justin J Kuhlman;Jing Wang
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
51.PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise

機譯：NHL 和 CLL 中的 PI3k 抑制劑：未兌現(xiàn)的承諾
- 作者：Naji Bou Zeid;Victor Yazbeck
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2023年第13期
52.Polycythemia Vera: Barriers to and Strategies for Optimal Management

機譯：真性紅細胞增多癥：最佳管理的障礙和策略
- 作者：Claire Harrison;Andrea Duminuco;Patrick Harrington;Natalia Curto-Garcia
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2023年第13期
53.Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy

機譯：大劑量甲氨蝶呤和基于大劑量 Ara-C 的基于 Ara-C 的 CNS 定向化學(xué)免疫療法與基于蒽環(huán)類藥物的化學(xué)免疫療法交替治療累及 CNS 的血管內(nèi)大 B 細胞淋巴瘤
- 作者：Vivek Gupta;Liuyan Jiang;Han W Tun;Muhamad Alhaj Moustafa;Karan Seegobin;Justin J Kuhlman;Jing Wang
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
54.90Yttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Report of 5 Cases

機譯：90釔 Ibritumomab Tiuxetan （Zevalin）治療慢性淋巴細胞白血病/小淋巴細胞淋巴瘤：5 例報告
- 作者：Firas Baidoun;Han W Tun;Jing Wang;Muhamad Alhaj Moustafa
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2023年第13期
55.A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?

機譯：濾泡性和彌漫性大 B 細胞淋巴瘤的精確表觀遺傳學(xué)治療的前景光明？
- 作者：Clement Chung
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
56.How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice

機譯：我如何管理慢性粒細胞白血病（CML）患者：臨床實踐的觀點
- 作者：Guru Subramanian Guru Murthy
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
57.Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy

機譯：天冬酰胺酶治療成人急性淋巴細胞白血?。寒斍白C據(jù)和治療中的地位
- 作者：Krishna R Juluri;Chloe Siu;Ryan D Cassaday
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2022年第12期
58.Identification of a Prognostic Model Based on NK Cell-Related Genes in Multiple Myeloma Using Single-Cell and Transcriptomic Data Analysis

機譯：使用單細胞和轉(zhuǎn)錄組學(xué)數(shù)據(jù)分析鑒定多發(fā)性骨髓瘤中基于 NK 細胞相關(guān)基因的預(yù)后模型
- 作者：Sha Gong;Lu Wang;Huaiyu Wang;Nan Mei;Jincheng Wang;Huanming Zhang;Jianpeng Li;Yingying Bao;Lizhao Wang
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2024年第14期
59.Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review

機譯：Zanubrutinib 在套細胞淋巴瘤管理中的應(yīng)用：綜合綜述
- 作者：Nada Alsuhebany;Eileen Holovac;Brian Do;Ali McBride;Congshan Pan
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2023年第13期
60.The Antibody Drug Conjugate Belantamab-Mafodotin in the Treatment of Multiple Myeloma: A Comprehensive Review

機譯：抗體藥物偶聯(lián)物 Belantamab-Mafodotin 治療多發(fā)性骨髓瘤：綜合評價
- 作者：Wilson I Gonsalves;Samhar Samer Alouch;Yogesh Chawla;Adrian Alfonso Almodovar Diaz
- 期刊名稱：《Blood and Lymphatic Cancer: Targets and Therapy》 | 2024年第14期

国产bbaaaaa片,成年美女黄网站色视频免费,成年黄大片,а天堂中文最新一区二区三区,成人精品视频一区二区三区尤物

Blood and Lymphatic Cancer: Targets and Therapy